8-K: Cardinal Health Boosts FY26 EPS Outlook, Citing Strong Specialty Growth

Cardinal Health has raised its fiscal year 2026 non-GAAP diluted earnings per share outlook to at least $10.00, driven by accelerating specialty growth and successful navigation of IRA changes.

Summary

• Cardinal Health increased its fiscal year 2026 non-GAAP diluted earnings per share (EPS) outlook to at least $10.00, up from the prior guidance range of $9.65 to $9.85.
• Specialty revenues are projected to exceed $50 billion in fiscal 2026, representing a 16% compounded annual growth rate over three years (FY24-FY26 from FY23 baseline).
• BioPharma Solutions is expected to achieve over 30% revenue growth in fiscal 2026, with its Sonexus Access and Patient Support business securing new partnerships serving over 1 million patients, including Sanofi and Regeneron's Dupixent My Way program.
• The company successfully transitioned manufacturer distribution service agreements for all branded pharmaceutical products affected by the 2026 Medicare Drug Price Negotiation Program prior to the January 1st implementation date.
• The at-Home Solutions business launched the ContinuCare Pathway program, simplifying diabetes supply management, and secured a key partnership with Publix Super Markets Inc., expanding the program to over 11,000 pharmacies.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with raised earnings guidance, strong growth projections in key segments, successful navigation of regulatory changes, and new strategic partnerships. The tone is confident and highlights significant progress.

Positives

• Increased fiscal year 2026 non-GAAP diluted EPS outlook to at least $10.00, demonstrating strong performance and confidence.
• Anticipated Specialty revenues exceeding $50 billion in fiscal 2026, reflecting a robust 16% compounded annual growth rate over three years.
• Strong projected revenue growth of over 30% in BioPharma Solutions for fiscal 2026, driven by significant wins for its Sonexus Access and Patient Support business.
• Successful navigation and transition of manufacturer distribution service agreements related to the 2026 Medicare Drug Price Negotiation Program, ensuring continued appropriate compensation.
• Introduction of the innovative ContinuCare Pathway program and a major partnership with Publix Super Markets Inc., expanding its reach to over 11,000 pharmacies and enhancing patient access to diabetes supplies.

Risks

• Ability to navigate uncertainties arising from proposed or final regulatory changes, including those related to pharmaceutical pricing and tariffs.
• Managing uncertainties associated with the pricing of branded pharmaceuticals.
• Risk of failing to achieve strategic objectives, including the continued execution of the GMPD Improvement Plan initiatives.
• Risks associated with recent acquisitions, including entry into new lines of businesses and challenges with business integration.
• Competitive pressures in various lines of business, including the risk of customers reducing purchases, terminating, or not renewing contracts due to price increases or other factors.
• Risks associated with litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• Potential impact of events outside of company control, such as weather or geopolitical events, on product demand or causing supply shortages.
• Performance of the generics program, including the amount or rate of generic deflation and the ability to offset it and maintain financial benefits.

Future Outlook

Cardinal Health is confident in its strategic growth plan, raising its fiscal year 2026 non-GAAP diluted EPS outlook to at least $10.00. The company anticipates Specialty revenues to exceed $50 billion in fiscal 2026, driven by robust demand and significant growth in BioPharma Solutions. It also expects to continue being appropriately compensated for its role in healthcare despite changes from the 2026 Medicare Drug Price Negotiation Program.

Management Comments

• "Our team's execution against our strategic growth plan continues to deliver meaningful results, and as a demonstration of our confidence and momentum, we are pleased to again raise our expectations for fiscal year 2026." Jason Hollar, CEO of Cardinal Health.

Industry Context

This announcement positions Cardinal Health as a strong performer in the pharmaceutical distribution and specialty products sector, demonstrating resilience and adaptability in navigating regulatory changes like the Medicare Drug Price Negotiation Program. The focus on specialty growth and direct-to-patient solutions aligns with broader industry trends towards personalized healthcare and efficient supply chain management, particularly in high-growth areas like diabetes care and complex biologics. The company's success in securing major patient support hub programs, including Dupixent My Way, highlights its competitive strength in a market increasingly reliant on comprehensive patient services.

Comparison to Industry Standards

• NA

Legal Proceedings

• Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act are a risk.

Stakeholder Impact

• Shareholders: Positive impact due to raised earnings guidance and strong growth prospects, potentially leading to increased share value.
• Customers (Pharmacies, Hospitals, Manufacturers): Enhanced service offerings through programs like ContinuCare Pathway and expanded patient support hubs (Sonexus), improving supply chain efficiency and patient access.
• Patients: Improved access to diabetes supplies through ContinuCare Pathway and enhanced patient support services for complex therapies.
• Employees: Continued strong performance and strategic growth initiatives may indicate job stability and potential for growth within the company.
• Suppliers: Continued demand for pharmaceuticals and medical products.

Next Steps

• Provide further details and updates on the upcoming second quarter earnings call on February 5, 2026.
• Continue execution against the strategic growth plan.
• Present at the J.P. Morgan Healthcare Conference on January 13, 2026.

Key Dates

Recommendation

The significant upward revision of fiscal year 2026 EPS guidance, coupled with robust growth projections in the high-margin Specialty segment and successful mitigation of regulatory risks (IRA changes), indicates strong operational execution and positive momentum. The expansion of patient support services and strategic partnerships further solidifies Cardinal Health's market position. These factors suggest a strong financial trajectory and undervaluation potential, warranting a 'strong buy' recommendation for investors.

Keywords

Cardinal Health, CAH, Earnings Outlook, EPS Guidance, Specialty Growth, BioPharma Solutions, Medicare Drug Price Negotiation Program, IRA Changes, ContinuCare Pathway, Diabetes Supply Management, Healthcare Conference, Pharmaceutical Distribution, Medical Products